Baricitinib drug-Cipla moves into a licensing pact with Eli Lilly

Must read

To expand access to Covid 19 treatment in India, Cipla made an announcement that it has moved into a licensing agreement with American pharma company Eli Lilly on Monday. The company has already signed a royalty-free, non-exclusive voluntary licensing agreement with pharma company Eli Lilly to manufacture and commercialize the drug Baricitinib for Covid-19 indication in the announcement Cipla added.

Mainly, Baricitinib drug was issued a Restricted Emergency Use Approval by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India, requiring supplemental oxygen, aggressive, in hospitalized adults. Mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Cipla limited said it’ll leverage its extensive distribution footprint to make this therapy accessible to more patients and markets. 

Umang Vohra, MD, and Global CEO, Cipla Ltd, said, “Enabling access to high-quality treatment and medicine is the main one for our purpose of ‘caring for life’. Through the .’idemic, Cipla was at the forefront of COVID care, and our partnership with Lilly is a demonstration of our unwavering commitment to care for patients affected by COVID-19. “

India is facing a severe shortage of essential drugs, equipment, and medical oxygen in the form of Kovid-19. Several countries, including the US, UK, Canada, other European Union, and Gulf countries, have come out in support. However, major cities such as Delhi and Mumbai continue to die due to a lack of essential medicines and medical oxygen.

More articles

- Advertisement -

Startup

Zeta India’s Revenue Jumps Over 2X To INR 305 Cr In FY21, Loss Widens To INR 43 Cr

Zeta’s revenue from operations rose to INR 297 Cr in FY21, a 2.4X jump from INR 121.5 Cr in FY20 The startup’s loss widened...
- Advertisement -

Latest article